Navigation Links
Promising and perilous? The ambivalent role of the CXCL12/ CXCR4 axis in heart repair
Date:11/30/2011

The chemokine CXCL12 acts as a chemical signal which mobilizes hematopoietic and other types of stem cells to leave the bone marrow and enter the circulation. Secretion of CXCL12 also guides these cells to sites at which the perfusion of tissue is sub-optimal due to localized obstruction of blood flow. These capabilities have made CXCL12 and its cognate receptor CXCR4 interesting candidates for therapies aimed at mitigating the effects of damage to the heart caused by myocardial infarction.

A team of researchers led by Professor Christian Weber of the Medical Center of the University of Munich has now taken a closer look at the normal physiological function of this ligand-receptor couple. Their results reveal that the molecules have "rather ambivalent roles," as Weber puts it.

Myocardial infarction remains one of the leading causes of death in Western societies. The condition occurs when parts of the heart muscle can no longer be adequately supplied with oxygen because blood flow through the coronary arteries is impeded. Researchers have therefore suggested that CXCL12 and CXCR4 could perhaps be used therapeutically to direct stem cells required for the formation of new blood vessels to migrate into ischemic, i.e. poorly perfused, tissues and thus help to increase blood flow in such areas.

"The precise physiological functions of the chemokine and its receptor are poorly understood, although these are the crucial determinants of their therapeutic potential and of possible side-effects," Weber points out. "We therefore studied the effects of infarction in an animal model in which the amount of CXCR4 produced is specifically reduced. We focused on the molecular and cellular consequences of infarction, particularly with respect to the recovery of cardiac function, formation of scar tissue, severity of inflammation, and neovascularization of heart muscle."

To their surprise the researchers found that reduction of the CXCR4 level correlated with significant reductions in infarct size and the degree of tissue inflammation, but that recovery of blood flow and neovascularization were concomitantly decreased. These opposing effects together meant that heart function was equally impaired whether or not the level of CXCR4 function was reduced.

"However, we did see some evidence for an improvement in adaptation to sub-optimal levels of oxygen," Weber remarks. "Although we cannot assume that these results are immediately applicable to the human heart, they do point toward the possibility especially in the case of systemic therapy of quite critical side-effects. We should perhaps focus on more localized approaches, such as the direct injection of stem cells with higher levels of CXCR4, or of CXCL12 variants that remain confined to the damaged areas of the heart or retain their activity in the coronary arteries for longer." (suwe/PH)


'/>"/>

Contact: Luise Dirscherl
dirscherl@lmu.de
49-892-180-2706
Ludwig-Maximilians-Universitt Mnchen
Source:Eurekalert

Related medicine news :

1. New artemisinin-based treatment against malaria promising
2. New Multiple Sclerosis Therapy Promising in Early Trial
3. Promising Malaria Vaccine May Save Childrens Lives
4. Promising new approach to treating debilitating nervous system disease
5. FDG-PET appears promising for predicting prognosis of patients with inoperable NSCLC
6. New half-match bone marrow transplant procedure yields promising outcomes for cancer patients
7. DOE laboratories help develop promising new cancer fighting drug, vemurafenib
8. Experimental Drug Promising Against Tough-to-Treat Asthma
9. INFORMS: CARE positions disaster relief with promising discipline of humanitarian logistics
10. Massachusetts General Hospital, Iacocca Foundation announce promising results of Phase I diabetes trial
11. Fighting cancer with cancer: Mayo Clinic finds promising use for thyroid cancer gene
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... , ... The American Board of Family Medicine's (ABFM) Board of Directors has ... succeeding Dr. James C. Puffer upon his retirement. Dr. Newton will serve in the ... at the end of 2018. Upon assuming the role of President and CEO on ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... ‘17, and Jennifer Huggins, PharmD ’17, along with clinical associate professor Janice ... of cardiovascular diseases during the 15th Annual Women’s Health Conference. The SIU ...
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term insurance ... care insurance companies have a waiver for care if the client has a cognitive ... the family pays for care, is often waived, so the benefits from their insurance ...
(Date:10/13/2017)... ... ... Global Healthcare Management’s 4th Annual Kids Fun Run brought out many kids ... sponsored by Global Healthcare Management’s CEO, Jon Letko, is aimed at getting kids excited ... all ages; it is a non-competitive, non-timed event, which is all about having fun ...
(Date:10/13/2017)... Fairfax, VA (PRWEB) , ... October 13, 2017 ... ... provider of DevOps and Agile Software Development, has been awarded a contract by ... (EATS) Blanket Purchase Agreement (BPA) aims to accelerate the enterprise use of Agile ...
Breaking Medicine News(10 mins):
(Date:10/11/2017)... Oct. 11, 2017  Caris Life Sciences ® , ... the promise of precision medicine, today announced that St. ... Precision Oncology Alliance™ (POA) as its 17 th ... St. Jude Crosson Cancer Institute will help develop standards ... of tumor profiling, making cancer treatment more precise and ...
(Date:10/11/2017)... , Oct. 11, 2017  Hill-Rom Holdings, Inc. ... Aspen Surgical facility in Las Piedras, Puerto ... scalpels and blades. ... that the facility sustained minor structural damage, temporary loss ... Maria. Repairs have been completed, manufacturing operations have resumed, ...
(Date:10/10/2017)... --  West Pharmaceutical Services, Inc. (NYSE: WST), a ... today shared the results of a study highlighting the ... administration of polio vaccines. The study results were presented ... by Dr. Ondrej Mach , Clinical Trials and ... and recently published in the journal Vaccine. i ...
Breaking Medicine Technology: